TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22901359

Group type: EXPERIMENTAL
Intervention: MK-0249 5-10 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate 54-72 mg/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: MK-0249
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20077576

Group type: EXPERIMENTAL
Intervention: Open kinetic chain exercises
Number of subjects: 27

Group type: COMPARATOR
Intervention: Closed kinetic chain exercises
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both intervention groups (open and closed kinetic chain exercises)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 27
Study: 17084625

Group type: EXPERIMENTAL
Intervention: 2.0% DHEA cream applied twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo applied twice daily
Number of subjects: 75
Study: 16270721

Group type: EXPERIMENTAL
Intervention: Montelukast plus budesonide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formoterol plus budesonide
Number of subjects: 20
Study: 11801579

Group type: EXPERIMENTAL
Intervention: AmBisome (3 or 5 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AmBisome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study: 12579713

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with scleral flaps tightly sutured with releasable sutures (group 3)
Number of subjects: 120
Study: 8801243

Group type: EXPERIMENTAL
Intervention: Preinterview suggestion about depression
Number of subjects: 52
Study: 2228983

Group type: EXPERIMENTAL
Intervention: Modified multiple monitored ECT (MMECT) limited to two seizure inductions in a session
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional electroconvulsive therapy (ECT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Modified multiple monitored ECT (MMECT)
Number of subjects: 29
Study: 528125

Group type: EXPERIMENTAL
Intervention: Phentermine resin 30 mg for eight weeks followed by placebo for eight weeks (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Placebo for eight weeks followed by phentermine for eight weeks (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 16 weeks (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Placebo for eight weeks followed by phentermine for eight weeks (Group 4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Phentermine for 'slow losers'
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 'slow losers'
Number of subjects: 80
Study: 31437006

Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (vSPs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Real Standardized Patients (rSPs)
Number of subjects: 60
Study: 30744605

Group type: EXPERIMENTAL
Intervention: Pooled PCR testing of dried blood spots (DBS)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Individual patient testing
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Pooled PCR testing
Number of subjects: 1170
Study: 28874970

Group type: EXPERIMENTAL
Intervention: Prolonged physiotherapy and rehabilitation for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early surgical discectomy
Number of subjects: 60
Study: 26467327

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 121
Study: 23536720

Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb, OA5D5v2) administered i.v. once every three weeks in combination with erlotinib
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo administered in combination with erlotinib
Number of subjects: 137
Study: 21790275

Group type: EXPERIMENTAL
Intervention: Personalized e-mail newsletter
Number of subjects: 109

Group type: COMPARATOR
Intervention: Generic e-mail newsletter
Number of subjects: 109
Study: 19645607

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 19
Study: 15879360

Group type: EXPERIMENTAL
Intervention: Alcohol (0.55 g ethanol/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Drinking-water
Number of subjects: 8
Study: 12903918

Group type: EXPERIMENTAL
Intervention: Oral cleansing with an electric toothbrush and povidone-iodine solution before surgery, followed by rinsing twice a day after surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Systemic cephazolin administration (3 g x day(-1) for 5 days) without oral cleansing
Number of subjects: 32
Study: 10566428

Group type: EXPERIMENTAL
Intervention: Touchscreen information systems
Number of subjects: 345
Study: 8759983

Group type: EXPERIMENTAL
Intervention: Intramuscular fosphenytoin equimolar to oral phenytoin dose
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral phenytoin
Number of subjects: 240
Study: 2032595

Group type: EXPERIMENTAL
Intervention: Tandem colonoscopy
Number of subjects: 63
Study: 7125336

Group type: EXPERIMENTAL
Intervention: Low-dose naloxone (0.8 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose naloxone (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31000896

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) infusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no magnesium sulphate)
Number of subjects: 66
Study: 29110848

Group type: EXPERIMENTAL
Intervention: One nodule
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Two nodules
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Three nodules
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Four nodules
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: >4 nodules
Number of subjects: 3392
Study: 25511549

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 48
Study: 22517542

Group type: EXPERIMENTAL
Intervention: Bromelain 3000 FIP units
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21640839

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI; selective serotonergic reuptake inhibitor)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reboxetine (SNRI; selective noradrenergic reuptake inhibitor)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18303229

Group type: EXPERIMENTAL
Intervention: Infiniti vision system
Number of subjects: 39

Group type: COMPARATOR
Intervention: Series 20,000 Legacy system
Number of subjects: 39
Study: 17167299

Group type: EXPERIMENTAL
Intervention: Intensive medical intervention and sixteen 90-minute supervised exercise sessions over 8 weeks (n=126)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (n=125)
Number of subjects: 251
Study: 15569338

Group type: EXPERIMENTAL
Intervention: Argatroban regimen A: 250-microg/kg bolus, with an additional 250-microg/kg bolus allowed
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Argatroban regimen B: 250-microg/kg bolus followed by 2-microg/kg/min infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Argatroban regimen C: steady-state, 2-microg/kg/min infusion initiated 4 hours before dialysis
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All regimens (A, B, C)
Number of subjects: 13
Study: 11426017

Group type: EXPERIMENTAL
Intervention: Low-dose d-penicillamine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: High-dose d-penicillamine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Previous controlled SSc trials (control group)
Number of subjects: 134
Study: 9298518

Group type: EXPERIMENTAL
Intervention: Amisulpride (800 mg/day)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 191
Study: 7961554

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (initial 6-week trial)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (continued treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clozapine treatment with plasma concentrations above 350 ng/mL
Number of subjects: 29
Study: 3498747

Group type: EXPERIMENTAL
Intervention: NSAIDs (specific drugs include indomethacin and naproxen)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: NSAIDs (specifically indomethacin, 150 mg/day)
Number of subjects: 444

Group type: COMPARATOR
Intervention: NSAIDs (in control group)
Number of subjects: 444
Study: 30545531

Group type: EXPERIMENTAL
Intervention: Novafen
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 168
Study: 27463942

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 17322

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 17322
Study: 25043068

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery ablation (thoracoscopy group, n = 66)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Catheter ablation (catheter group, n = 72)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery ablation (thoracoscopy group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Catheter ablation (catheter group)
Number of subjects: 138
Study: 22824225

Group type: EXPERIMENTAL
Intervention: Pragmatic randomized controlled trial design
Number of subjects: 0
Study: 20409284

Group type: EXPERIMENTAL
Intervention: Water and Health Education (W/HE) programme
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 557
Study: 18424099

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 1280 mg daily for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE)
Number of subjects: 75
Study: 16604429

Group type: EXPERIMENTAL
Intervention: 30-session drug prevention program in 7th through 9th grades
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: 30-session drug prevention program in 7th through 9th grades (60% or more participation)
Number of subjects: 2042
Study: 14971524

Group type: EXPERIMENTAL
Intervention: Methyldopa 250 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10890661

Group type: EXPERIMENTAL
Intervention: Gastric insufflation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard insertion technique)
Number of subjects: 50
Study: 8940228

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 42
Study: 1405378

Group type: EXPERIMENTAL
Intervention: Experimental group with increased Kt/V (urea) (initial Kt/V (urea) 0.82 +/- 0.19; final Kt/V (urea) 1.32 +/- 0.21)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with unchanged Kt/V (urea) (initial Kt/V (urea) 0.82 +/- 0.16; final Kt/V (urea) 0.87 +/- 0.15)
Number of subjects: 30
Study: 2876744

Group type: EXPERIMENTAL
Intervention: 2 g sulphasalazine daily for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28234714

Group type: EXPERIMENTAL
Intervention: SIC session with HPMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: SIC session without HPMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control session with HPMS ingestion only
Number of subjects: 14
Study: 27307573

Group type: EXPERIMENTAL
Intervention: Chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a multiepitope string fused to TRAP and 3 doses of RTS,S/AS01B (group 1; n=20)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3 doses of RTS,S/AS01B alone (group 2; n=17)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (unvaccinated; n=6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Repeat CHMI after 6 months (group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Repeat CHMI after 6 months (group 2)
Number of subjects: 37
Study: 23102675

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B-TURP)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M-TURP)
Number of subjects: 295
Study: 21953739

Group type: EXPERIMENTAL
Intervention: Intensive phonics-based intervention program for reading difficulties, tailored to Swedish orthography, one-to-one tutoring for twelve weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intensive phonics-based intervention program for reading difficulties
Number of subjects: 112
Study: 19391032

Group type: EXPERIMENTAL
Intervention: JuicePlus + (nutritional product composed primarily of dehydrated juice concentrates from mixed fruits and vegetables) for 28 days
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: JuicePlus + (nutritional product)
Number of subjects: 92
Study: 17710003

Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine every 6, 12, or 24 hours plus methylprednisolone every 4 to 5 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single injection of bupivacaine and methylprednisolone at intervals of 4 to 5 days
Number of subjects: 160
Study: 15601521

Group type: EXPERIMENTAL
Intervention: MTL-P300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMTL-N400
Number of subjects: 0
Study: 11496850

Group type: EXPERIMENTAL
Intervention: Nelfinavir plus efavirenz
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 195

Group type: COMPARATOR
Intervention: Quadruple therapy (nelfinavir plus efavirenz and two nucleoside analogues)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Triple therapy with efavirenz
Number of subjects: 195

Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 195
Study: 9919013

Group type: EXPERIMENTAL
Intervention: Lobeline HCl (intravenous injections in incremental doses)
Number of subjects: 15
Study: 8116700

Group type: EXPERIMENTAL
Intervention: Atosiban (300 micrograms/min for 2 hours)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atosiban and Placebo
Number of subjects: 120
Study: 3056445

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (added to primary drug)
Number of subjects: 0
Study: 31769395

Group type: EXPERIMENTAL
Intervention: Reactive case detection (RACD) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Private health facilities (HF)
Number of subjects: 40
Study: 30928650

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 605
Study: 28347835

Group type: EXPERIMENTAL
Intervention: >40% reduced standardized activity level (SAL)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: >40% reduced SAL (after adjustment for clinical covariates)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Decline in SAL following a nonfatal VTA and HFE
Number of subjects: 1008
Study: 24297379

Group type: EXPERIMENTAL
Intervention: SrRan 2 g/day
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: SrRan 1 g/day
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 24660579

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (50 sessions)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Seretide (salmeterol 50 µg/fluticasone 250 µg, twice a day)
Number of subjects: 288
Study: 22134677

Group type: EXPERIMENTAL
Intervention: Childcare discount of $8.92 per session attended
Number of subjects: 174

Group type: COMPARATOR
Intervention: No financial incentive (control group)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Childcare discount
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Cost simulations
Number of subjects: 174
Study: 19841119

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral formula feeding
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no pain relief intervention)
Number of subjects: 180
Study: 22835927

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (no adenoidectomy)
Number of subjects: 217
Study: 15768570

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Group Motivational Intervention (GMI)
Number of subjects: 230
Study: 12444940

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 120 mg (subsequently 60 mg) once daily
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 9481724

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 12 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 4 g betaine daily for 12 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1 mg folic acid daily for 40 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 40 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 15 mg folic acid daily for four weeks
Number of subjects: 35
Study: 8550857

Group type: EXPERIMENTAL
Intervention: MOTS CPC (6.6 mg cetylpyridinium chloride), 2 x daily for 2 hours intra-orally
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Peridex (15 ml, 2 x daily for 30 seconds rinsing)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cepacol (1.6 mg cetylpyridinium chloride, 2 x daily lozenges)
Number of subjects: 52
Study: 2677961

Group type: EXPERIMENTAL
Intervention: Milk-based diet containing 6 g/kg of body weight per day of lactose
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hydrolyzed lactose diet (greater than 95% prehydrolyzed with beta-galactosidase)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hydrolyzed lactose diet
Number of subjects: 64
Study: 642095

Group type: EXPERIMENTAL
Intervention: Prophylactic aminoglycoside (kanamycin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no prophylactic antibiotics)
Number of subjects: 100
Study: 29757825

Group type: EXPERIMENTAL
Intervention: Exercise training and education (ET + ED)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Exercise training alone (ET)
Number of subjects: 198
Study: 26607102

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) after stepwise drug discontinuation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Maintenance treatment (MT)
Number of subjects: 19
Study: 24823925

Group type: EXPERIMENTAL
Intervention: task‐oriented robot‐supported arm‐hand training
Number of subjects: 16

Group type: COMPARATOR
Intervention: task‐oriented (unsupported) arm‐hand training
Number of subjects: 16
Study: 23601012

Group type: EXPERIMENTAL
Intervention: Visual feedback of personal retinal images
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 20147417

Group type: EXPERIMENTAL
Intervention: Conscious correction group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Distraction group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 18155963

Group type: EXPERIMENTAL
Intervention: 0.01 microg rdESAT-6
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.1 microg rdESAT-6
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 microg rdESAT-6
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tuberculin (2 TU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rdESAT-6 (10 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rdESAT-6 (all doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tuberculin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rdESAT-6
Number of subjects: 15
Study: 15665706

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Cefprozil
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 1009
Study: 12499323

Group type: EXPERIMENTAL
Intervention: Equal-iron peanut butter-based diet
Number of subjects: 77

Group type: COMPARATOR
Intervention: Olive oil diet
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Iron status measures (ferritin, iron, TIBC, NTBI)
Number of subjects: 77
Study: 10817444

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study: 9102031

Group type: EXPERIMENTAL
Intervention: Commercial pure titanium implants
Number of subjects: 281

Group type: COMPARATOR
Intervention: Stainless steel implants
Number of subjects: 281
Study: 2050913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7040157

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard treatment (hydration and tetracycline)
Number of subjects: 410
Study: 30354530

Group type: EXPERIMENTAL
Intervention: 8% DSP-Visulex
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 15% DSP-Visulex
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prednisolone acetate (PA)
Number of subjects: 44
Study: 30058437

Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil anesthesia
Number of subjects: 67

Group type: COMPARATOR
Intervention: TIVA (propofol/remifentanil) anesthesia
Number of subjects: 67
Study: 26254238

Group type: EXPERIMENTAL
Intervention: Patient decision aids (PtDA)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control (usual education)
Number of subjects: 343
Study: 24679880

Group type: EXPERIMENTAL
Intervention: Dissolution therapy with potassium sodium hydrogen citrate at a dose of 1 mEq/kg per day for 1 to 3 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Shock wave lithotripsy using a Lithotripter S under general anesthesia
Number of subjects: 87
Study: 23059918

Group type: EXPERIMENTAL
Intervention: Dexamethasone ointment (5 g tube containing 5 mg dexamethasone)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 240